Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

This study found that sebaceous glands predominantly exhibit oxidative activity of the type 2 17β-hydroxysteroid dehydrogenase isozyme, which is not inhibited by 13-cis retinoic acid.

This study found that SZ95 sebocytes and HaCaT keratinocytes exhibit distinct enzyme expressions and activities, implicating their different roles in androgen metabolism and homeostasis in vitro.

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

This study found that Avicennia marina extract and its active compound avicequinone C inhibit enzymes and receptors related to androgenic alopecia, potentially supporting hair growth in cultured dermal papilla cells.

In this study, researchers developed a sensitive assay to measure the inhibition of steroid 5-α reductase (5AR) by chemicals like finasteride and dutasteride, revealing species-specific differences in inhibitor efficacy between human and fish cell lines.

This study observes the expression of mRNA for androgen receptor, 5α‐reductase, and 17β‐hydroxysteroid dehydrogenase in human dermal papilla cells.

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.

This review highlights the challenges in screening for steroid 5 alpha-reductase inhibitors and discusses significant variability in the effectiveness of finasteride and dutasteride, calling for standardized testing methods to develop safer, more specific inhibitors from herbal preparations.

This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.

This study found that novel compounds moderately inhibited 5α-reductase type 1 activity compared to finasteride, offering valuable data on structure-activity relationships.

This study used machine learning to develop classifiers for identifying effective inhibitors of 5α-reductase isozyme 2, achieving high performance in distinguishing potent from weak inhibitors.

This study reports that five new progesterone derivatives demonstrated inhibitory activity against the 5α-reductase enzyme and binding affinity for the androgen receptor in an in vitro hamster model.

In this study, Ganoderma lucidum extract was found to significantly inhibit 5alpha-reductase activity and testosterone-induced prostate growth in rats, suggesting potential use for treating benign prostatic hyperplasia.

This study found that the 5α-steroid metabolite profile in men with inherited 5α-reductase deficiency is similar to those taking the drug finasteride, suggesting the gene affects multiple steroid substrates.

This study reports that novel core-ABS nanocarriers efficiently loaded with dexamethasone and finasteride show potential for dermal drug delivery, exhibiting non-toxic interactions with human keratinocyte cells and skin penetration.

The researchers observed that normal murine hair follicles are direct targets for melatonin, with receptor expression varying throughout the hair cycle, suggesting melatonin's role in hair cycle control.

This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.

This study found that Ganoderma lucidum extracts showed weak 5alpha-reductase inhibition but significantly inhibited prostate cell proliferation and testosterone-driven prostate growth in rats, suggesting potential as an ingredient for treating androgen-induced diseases.

In castrated rats, this study found that triterpenoids from Ganoderma lucidum inhibited both types of 5α-reductase and reduced prostate growth linked to testosterone but not dihydrotestosterone.

Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.

In this study, germacrone from Curcuma aeruginosa showed anti-androgenic effects by inhibiting 5α-reductase, suggesting its potential as a lead compound for treating androgen-dependent disorders.

This article reviews the coordination of the hypothalamic-pituitary-gonadal axis, male fertility, and therapies for hypogonadism, but reports no new clinical findings.

This review discusses the relevance of human androgen receptor action in sports doping and examines the potential of cell-based biological assays for detecting androgenic anabolic steroid use, without presenting new research findings.

This study found that an ethanolic extract from the microalga Tetrathelmis tetrathele exhibited anti-inflammatory effects, promoted the proliferation of certain skin and hair cells, and inhibited 5α-reductase activity, suggesting its potential as a therapeutic agent for preventing alopecia and enhancing scalp health.

This article reviews differential diagnosis approaches for 46,XY DSD, proposing a diagnostic algorithm focused on biochemical and genetic data, without presenting new clinical results.

This paper discusses the role of steroid sulfatase in hormone-dependent tumors and highlights the development of potent inhibitors, noting the commencement of a phase I trial for one inhibitor in postmenopausal breast cancer patients.

This study suggests that the adrenal gland may contribute to prostate cancer treatment resistance and indicates potential steroid production or dependency in ovarian cancer.

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.